Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough

This article was originally published in The Tan Sheet

Executive Summary

Company's non-sedating antihistamine Claritin (loratadine) has been granted six months of pediatric exclusivity, Schering announces Aug. 16. The patent for Claritin was set to expire in June 2002, the company says. The studies Schering submitted in its request for additional marketing exclusivity also are part of supplemental NDAs for Claritin syrup to expand the indications to include children two to five years old. Claritin was discussed as an appropriate switch candidate at an FDA public meeting in June (1"The Tan Sheet" July 3, p. 3)
Advertisement

Related Content

Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA
Rx Antihistamine Switch Consumer Cost Increases Unlikely, Insurer Tells FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS091578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel